News - tabalumab, Pharmaceutical

Filter

Current filters:

tabalumabPharmaceutical

Popular Filters

Lack of efficacy causes Eli Lilly to drop Ph III RA program for tabalumab

08-02-2013

US drug major Eli Lilly (NYSE: LLY) says that it will discontinue the Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Eli Lilly drops one tabalumab trial for RA

14-12-2012

US drug major Eli Lilly (NYSE: LLY) says that it will stop one of three Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top